Metabolic dysfunction-associated steatohepatitis

CVRM · 3 drugs · 1 indications

Competitive Landscape (3 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Retatrutide	LLY	GLP-1/GIP/Glucagon triple agonist	Peptide	SC	PHASE3
Efinopegdutide	MRK	GLP-1/glucagon dual agonist	Peptide	SC	PHASE3
Zepbound	LLY	GLP-1/GIP dual agonist	Peptide	SC	APPROVED

Indications (1)

MASH

Upcoming Catalysts

Tirzepatide - MASH - Ph3 - Topline (SYNERGY-NASH)CLINICAL

LLY2026

Retatrutide - Obesity/CVD - Ph3 - Topline (TRIUMPH-3)CLINICAL

LLYFebruary 2026

Retatrutide - Obesity - Ph3 - Topline (TRIUMPH-1)CLINICAL

LLYApril 2026

Retatrutide - T2D - Ph3 - Topline (TRIUMPH-2)CLINICAL

LLYMay 2026

Zepbound - Medicare Part D AccessCOMMERCIAL

LLYJuly 1, 2026

Zepbound vs CagriSema - Obesity - Ph3 - Topline (REDEFINE-4)CLINICAL

LLYH2 2026

Retatrutide - Obesity - NDA SubmissionREGULATORY

LLYLate 2026

Data from Supabase · Updated 2026-03-24